Declan Doogan - Dec 10, 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Stock symbol
TENX
Transactions as of
Dec 10, 2024
Transactions value $
$0
Form type
4
Date filed
12/12/2024, 07:58 PM
Previous filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 2.27K Dec 10, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +100K $0.00 100K Dec 10, 2024 Common Stock 100K $5.94 Direct
holding TENX Stock Option (right tob buy) 4 Dec 10, 2024 Common Stock 4 $3,200.00 Direct F2
holding TENX Stock Option (right to buy) 4 Dec 10, 2024 Common Stock 4 $992.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The aggregate number of shares of common stock were previously reported as 3,637,871, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F2 These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F3 These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.